Exploring factors influencing patient outcomes in collapsed lung due to underlying lung disease

Submission date	Recruitment status No longer recruiting	Prospectively registered		
10/01/2023		[X] Protocol		
Registration date	Overall study status Completed	Statistical analysis plan		
20/03/2023		Results		
Last Edited	Condition category Respiratory	Individual participant data		
22/04/2024		Record updated in last year		

Plain English summary of protocol

Background and study aims

Secondary spontaneous pneumothorax (SSP) is a medical emergency where an abnormal collection of air develops in the space between the lung and the chest wall, causing lung collapse. This occurs in patients with existing lung diseases such as chronic obstructive pulmonary disease (COPD). In the UK, patients with SSP are usually treated by inserting a drain into the chest to remove the air. The drain is stitched in place and left until the air is completely removed. The drain typically remains in place for over a week, leading to long hospital stays. Sometimes these patients need surgery to help stop the air leaking into the lung, but it is also recognised that these patients may not be fit for major surgery. Unfortunately, we don't have data from UK patients about the key consequences of developing a secondary spontaneous pneumothorax. For example, we don't know how long patients stay in hospital, how many go for surgery, and how many develop complications. With this information we can better plan for care, but also look at why some patients stay longer in hospital and why some patients need surgery, whilst others don't. The aim of this study is to gather information about SSP in an attempt to answer some of these unknown questions. We will recruit patients admitted to hospital with SSP throughout the UK over a period of 1 year. We will collect routine data from the patient's records, such as age, medical history and how long they stay in the hospital.

Who can participate?

Any patient with a collapsed lung with known or suspected underlying lung disease OR who is over the age of 50 with a significant smoking history is eligible to participate in this study. Patients with a collapsed lung because of an injury or a medical intervention are not eligible.

What does the study involve?

This is an observational study, which means that nothing additional is required from participants outside of their routine care. They will be informed about the study and given the option to decline to participate. The study team will collect data on the patients' background, their medical history, whether they are or have been a smoker, how fit the patient is and data related to their collapsed lung and how it is managed. Further data will then be collected at 1 month and 6 months post-enrolment. There are no additional interventions required.

What are the possible benefits and risks of participating?

There are no direct clinical benefits to participants from engaging in this research as it is observational. Once the results are published, we hope that the knowledge obtained will benefit patients in the future by helping clinicians understand better how to manage patients with this condition, taking into account different factors that may influence their outcomes. The observational nature of this study means that there are no additional risks to patients from participating.

Where is the study run from?
The lead site is North Bristol NHS Trust (UK)

When is the study starting and how long is it expected to run for? May 2022 to September 2024

Who is funding the study? Rocket Medical Plc (UK)

Who is the main contact?

Dr Eleanor Barton, eleanor.barton@nbt.nhs.uk (UK)

Contact information

Type(s)

Scientific

Contact name

Dr Eleanor Barton

ORCID ID

https://orcid.org/0000-0003-0381-810X

Contact details

Pleural Clinical Research Fellow Academic Respiratory Unit North Bristol NHS Trust Southmead Hospital Bristol United Kingdom BS10 5NB +44 (0)117 414 8033 eleanor.barton@nbt.nhs.uk

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

Integrated Research Application System (IRAS)

316472

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

CPMS 53700, IRAS 316472

Study information

Scientific Title

Longitudinal investigation of secondary pneumothorax

Acronym

LISP

Study objectives

To determine the characteristics, healthcare burden, management and outcomes of patients with secondary spontaneous pneumothorax in the UK.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 01/12/2022, South West – Frenchay Research Ethics Committee (Ground Floor, Temple Quay House, 2 The Square, Bristol, BS1 6PN, UK; +44 (0)207 104 8106; frenchay.rec@hra.nhs.uk), ref: 22/SW/0125

Study design

Multicentre prospective longitudinal cohort study

Primary study design

Observational

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Secondary spontaneous pneumothorax

Interventions

Patients presenting with secondary spontaneous pneumothorax (SSP) to any of the hospitals involved in the study will be screened and invited to participate in the study by trained clinicians or research nurses. SSP is defined in this study as a spontaneous pneumothorax with no history of trauma or iatrogenic intervention preceding it in a patient with known or suspected lung disease or a patient over the age of 50 with a smoking history. Patients with SSP will almost exclusively require admission under a specialist respiratory team, and as such we anticipate high patient identification rates.

We will collect data on the patient's demographics, past medical history and history of current illness, smoking status including cannabis, asbestos and other inhalational exposures, clinical frailty score (CFS) and performance status (PS). We will also collect data related to the

pneumothorax and its management (e.g. digital or analogue assessment of air leak, size of the pneumothorax on CXR, procedures performed and their outcomes).

Further data will be collected from the patient's medical records at 1 month and 6 months post enrolment, to encompass the patient's length of stay, number and type of interventions, recurrence, and mortality. These two-time points allow for the collection of complete data sets, acknowledging that some patients may have a prolonged stay exceeding 1 month and ensuring that enough time has elapsed to capture the incidence of recurrence.

Intervention Type

Other

Primary outcome(s)

- 1. Patient demographics: age (years), gender (M/F), socioeconomic status (Index of multiple deprivations) measured from the patient's medical records at baseline
- 2. Number and type of procedures required (number, procedures performed) measured from the patient's medical records at baseline, 1 month and 6 months
- 3. Outcomes: Length of stay (days), air leak duration (days), mortality (death rate) measured from the patient's medical records at baseline, 1 month and 6 months

Key secondary outcome(s))

There are no secondary outcome measures

Completion date

30/09/2024

Eligibility

Key inclusion criteria

- 1. Emergency attendance to hospital with secondary spontaneous pneumothorax (SSP), confirmed by radiology, with SSP defined as spontaneous pneumothorax in presence of known or suspected lung disease OR spontaneous pneumothorax
- 2. Aged ≥50 years old
- 3. History of smoking

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

16 years

Upper age limit

50 years

Sex

Total final enrolment

213

Key exclusion criteria

- 1. Aged <16 years old
- 2. Latrogenic pneumothorax
- 3. Traumatic pneumothorax

Date of first enrolment

15/02/2023

Date of final enrolment

31/03/2024

Locations

Countries of recruitment

United Kingdom

England

Wales

Study participating centre Southmead Hospital

Southmead Road Westbury-on-trym Bristol United Kingdom BS10 5NB

Study participating centre Maidstone Hospital

Hermitage Lane Maidstone United Kingdom ME16 9QQ

Study participating centre Worthing Hospital

Lyndhurst Road

Worthing United Kingdom BN11 2DH

Study participating centre Royal Devon University Healthcare NHS Foundation Trust

Royal Devon University NHS Ft Barrack Road Exeter United Kingdom EX2 5DW

Study participating centre Northern General Hospital

Herries Road Sheffield United Kingdom S5 7AU

Study participating centre John Radcliffe Hospital

Headley Way Headington Oxford United Kingdom OX3 9DU

Study participating centre Dewi Sant Hospital

Albert Road Pontypridd United Kingdom CF37 1LB

Study participating centre Torbay Hospital

Newton Road Torquay United Kingdom TQ2 7AA

Study participating centre St Thomas' Hospital

Westminster Bridge Road London United Kingdom SE1 7EH

Study participating centre Freeman Hospital

Freeman Road High Heaton Newcastle upon Tyne United Kingdom NE7 7DN

Study participating centre Derriford Hospital

Derriford Road Crownhill Plymouth United Kingdom PL6 8DH

Study participating centre Yeovil District Hospital

Higher Kingston Yeovil United Kingdom BA21 4AT

Study participating centre Queen Elizabeth Hospital

Mindelsohn Way Edgbaston Birmingham United Kingdom B15 2TH

Study participating centre

Worcestershire Royal Hospital

Charles Hastings Way Worcester United Kingdom WR5 1DD

Study participating centre Aneurin Bevan University Lhb

Headquarters - St Cadoc's Hospital Lodge Road Caerleon Newport United Kingdom NP18 3XQ

Study participating centre North Tyneside General Hospital

Rake Lane North Shields United Kingdom NE29 8NH

Study participating centre Arrow Park Hospital

Arrowe Park Road Wirral United Kingdom CH49 5PE

Study participating centre Harrogate District Hospital

Lancaster Park Road Harrogate United Kingdom HG2 7SX

Study participating centre University Hospitals of North Midlands NHS Trust

Newcastle Road

Stoke-on-trent United Kingdom ST4 6QG

Study participating centre Norfolk and Norwich University Hospital

Colney Lane Colney Norwich United Kingdom NR4 7UY

Sponsor information

Organisation

North Bristol NHS Trust

ROR

https://ror.org/036x6gt55

Funder(s)

Funder type

Government

Funder Name

National Institute for Health and Care Research

Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Funder Name

Rocket Medical Plc

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are not expected to be made available as patients did not consent to this level of data sharing.

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
HRA research summary			28/06/2023		No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Protocol file	version 1.2	21/12/2022	14/01/2023	No	No
Study website	Study website	11/11/2025	11/11/2025	No	Yes